Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | RAPGEF4 | Q8WZA2 | 6/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6382158 | 0.92 | ALDH1A1 (0.40) | MEN1ALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL11966928 | 0.87 | ALDH1A1 (0.40) | MEN1ALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL15025688 | 0.87 | ADORA3 (0.40) | MEN1ALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL9876053 | 0.86 | ALDH1A1 (0.50) | MEN1ALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL12622364 | 0.85 | PDGFRB (0.40) | MEN1ALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL22421482 | 0.82 | RAPGEF4 (0.41) | MEN1ALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL23735474 | 0.82 | ALDH1A1 (0.36) | MEN1ALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL2843928 | 0.82 | ALDH1A1 (0.40) | MEN1ALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL17180546 | 0.82 | PSMB5 (0.47) | MEN1ALDH1A1KMT2ASMN1; SMN2ACHE | |
| SCHEMBL3928038 | 0.82 | RAPGEF4 (0.50) | MEN1ALDH1A1MAPTKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4395521-A1 | CONDENSED CYCLIC COMPOUND, LIGHT-EMITTING DEVICE COMPRISING THE CONDENSED CYCLIC COMPOUND, AND ELECTRONIC APPARATUS COMPRISING THE LIGHT-EMITTING DEVICE | Samsung Display Co., Ltd. (KR) | 2024-07-03 | — | — | EP | disclosed |
| EP-3725793-B1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE ORGANOMETALLIC COMPOUND, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND | SAMSUNG ELECTRONICS CO LTD (KR) | 2023-10-11 | — | — | EP | disclosed |
| EP-4198164-A1 | MIXED LAYER, METHOD OF PREPARING THE MIXED LAYER, LIGHT-EMITTING DEVICE, AND ELECTRONIC APPARATUS | Samsung Electronics Co., Ltd. (KR) | 2023-06-21 | — | — | EP | disclosed |
| EP-2438989-B1 | USE OF ASYMMETRIC HYDROGENATION CATALYST | TAKASAGO PERFUMERY CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 2015-08-13 | — | — | US | disclosed |
| US-9061959-B2 | Method for manufacturing optically active menthol | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-06-23 | — | — | US | disclosed |
| US-9000192-B2 | Catalyst for asymmetric hydrogenation and method for manufacturing optically active carbonyl compound using the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-04-07 | — | — | US | disclosed |
| US-8987304-B2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| US-8674144-B2 | Catalyst for asymmetric hydrogenation and method for manufacturing optically active carbonyl compound using the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-03-18 | — | — | US | disclosed |
| EP-2647616-A1 | METHOD FOR MANUFACTURING OPTICALLY ACTIVE MENTHOL | Takasago International Corporation (JP) | 2013-10-09 | — | — | EP | disclosed |
| EP-2543437-A2 | HOMOGENEOUS ASYMMETRIC HYDROGENATION CATALYST | Takasago International Corporation (JP) | 2013-01-09 | — | — | EP | disclosed |
| EP-2493906-A1 | HETEROLEPTIC CARBENE COMPLEXES AND USE THEREOF IN ORGANIC ELECTRONICS | BASF SE (DE) | 2012-09-05 | — | — | EP | disclosed |
| US-8217204-B2 | Catalyst for asymmetric hydrogenation | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| WO-2012074128-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-06-07 | — | — | WO | disclosed |
| US-20120136176-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-05-31 | — | — | US | disclosed |
| EP-2457655-A2 | Catalyst for asymmetric hydrogenation comprising peptides and method for manufacturing optically active carbonyl compound using the same | Takasago International Corporation (JP) | 2012-05-30 | — | — | EP | disclosed |
| WO-2011051404-A1 | HETEROLEPTIC CARBENE COMPLEXES AND USE THEREOF IN ORGANIC ELECTRONICS | BASF SE (DE) | 2011-05-05 | — | — | WO | disclosed |
| EP-2269694-A2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-12-23 | — | — | US | disclosed |
| US-20090275528-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | H1-0, H1-5, ADH5 | MEN1 1458/4885ALDH1A1 223/4885MAPT 2035/4885 |
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MEN1 2729/4885ALDH1A1 704/4885MAPT 1855/4885 |
| US-20120136176-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME | HMOX1, HIRA, HRH1 | MEN1 660/4885ALDH1A1 122/4885MAPT 1810/4885 |
| US-20090275528-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MEN1 2729/4885ALDH1A1 704/4885MAPT 1855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.